In a significant development in biotechnology patent law, biotech genus claims defined solely by function are proving exceedingly difficult to enable. This has been evidenced time and again in recent court verdicts, continuing a trend set forth in the aftermath of Amgen v. Sanofi.Baxalta Incorporated v. Genentech Inc. is the latest in a series of cases holding that such claims are nearly impossible to fulfill under the outlined enablement requirement.
Genus claims in biotechnology patents have long hovered in a precarious legal position. Typically, these claims encompass a broad swathe of related technology and are defined by the function of the entity in question, often an antibody or protein. The writ of such claims has been a contentious issue among legal circles for years, and recent verdicts have added another layer of complexity to the matter.
According to rulings such as in Baxalta Incorporated v. Genentech Inc., it is nearly unattainable to fulfill the enablement requirement for claims only stating the activity of an antibody. This requirement, a crucial aspect of the patenting process, dictates that a patent’s specifications must clearly demonstrate how a person skilled in the art could make and use the invention without undue experimentation.
The aftermath of Amgen v. Sanofi has seen courts applying this standard more rigorously to genus claims, weakening the validity of many such claims in the field of biotechnology. In a bid to untangle the legal and scientific complications of this issue, the legal community, including firms like Kilpatrick Townsend & Stockton LLP, are determined to clarify the specifics of contention.
While the debate surrounding the enablement of genus claims in biotechnology continues to evolve, one thing is increasingly evident – the landscape of biotech patents is getting more challenging. Legal professionals and biotechnology companies are now navigating a fine line, balancing broad genus claims against the need to detail functional specifications that satisfy the evolving enablement standards of the courts.